Investment analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of GLMD stock opened at $3.38 on Friday. Galmed Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $10.80. The firm has a market capitalization of $17.05 million, a PE ratio of -1.41 and a beta of 0.69. The stock has a fifty day moving average of $3.62 and a two-hundred day moving average of $4.14.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($2.76) earnings per share (EPS) for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Further Reading
- Five stocks we like better than Galmed Pharmaceuticals
- What is the Dogs of the Dow Strategy? Overview and Examples
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- How to invest in marijuana stocks in 7 steps
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
- Transportation Stocks Investing
- MarketBeat Week in Review – 8/26 – 8/30
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
